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Abstract
A synovial stimulating protein (SSP) has previously been isolated from rheumatoid arthritis synovial fluid and from the
culture fluid of rheumatoid arthritis synovial fibroblasts. We have previously isolated, from skin fibroblast cultures, a 40 kDa
hirudin-binding protein, which had amino acid sequence homology with the SSP. We sought to clarify the relationship, if
any, between the SSP and the hirudin-binding protein. We show that the hirudin-binding protein is immunologically cross-
reactive with a protein identical with, or very similar to, the SSP. This hirudin-binding protein is produced by normal and
rheumatoid arthritis fibroblasts in culture, and also by cervical carcinoma cells. Traces of an SSP-like protein, and of proteins
intermediate in size between the SSP and the hirudin-binding protein, suggest that the hirudin-binding protein may be
proteolytically derived from the SSP. An SSP-like protein of about 200 kDa is present in all synovial fluid samples, arthritic
and normal, indicating that its presence is not a primary cause of rheumatoid arthritis. There is no evidence for the existence
of smaller fragments of the SSP-like protein in synovial fluid. A cDNA sequence, coding for part of the 40 kDa protein, has
been obtained. The derived amino acid sequence indicates that a domain, previously identified in the dishevelled gene from
Drosophila melanogaster, is present in this protein. Peptides predicted from the cDNA sequence were used to raise antisera,
which recognise both the 40 kDa protein and the SSP-like protein. One of the antibody preparations is a good inhibitor of
fibroblast proliferation, which confirms the autocrine growth-stimulatory role originally proposed for these
proteins. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Activated T-lymphocytes and plasma cells have
been identi¢ed in the synovial £uid of rheumatoid
arthritis (RA) patients [1], and it was shown that
synovial £uid contained an activating factor, which
acted in concert with interleukin-2 [2]. The factor was
puri¢ed from RA synovial £uid, and a similar pro-
tein shown to be present in the conditioned medium
of cultured RA synovial ¢broblasts. This synovial
stimulatory protein (SSP) acted as an autoantigen,
to which T-lymphocytes from RA patients responded
[3]. In SDS^PAGE, the SSP ran as a 205 kDa pro-
tein which, when eluted and re-electrophoresed, ap-
peared to consist of subunits of about 70 kDa. In
microsequencing experiments, partial trypsin diges-
tion of the 70 kDa protein yielded fragments of 40
kDa, 27 kDa and 25 kDa which had a common N-
terminal sequence [4].
In an investigation of the cellular growth-inhibi-
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tory properties of the leech thrombin inhibitor, hi-
rudin, we used hirudin-agarose a⁄nity columns to
isolate a speci¢c protein from human ¢broblast ex-
tracts, and from ¢broblast-conditioned culture me-
dium. This protein had a molecular weight of about
40 kDa, and N-terminal amino acid sequencing in-
dicated a high degree of identity with the common
N-termini of the tryptic fragments of the SSP of
Hain et al. [4]. These workers reported DINGG-
GATLPQPLYQTA- as this sequence, whereas we
obtained DINGGGATLPQPLYQTSGVLTA-, rep-
resenting 16/17 identical residues. More recent work
on the SSP has extended the sequence of these frag-
ments, and con¢rms that residue 17 is more likely to
be serine (B. Stuhlmuller, personal communication).
Our hirudin-binding isolate exhibited proteolytic ac-
tivity towards a chromogenic substrate peptide, and
we named it the hirudin-sensitive ¢broblast protein-
ase (HSFP; [5]). The same protein has been isolated
by others (R. Mans¢eld; H. Kim, personal commu-
nications), and the name, ‘DING protein’ (from the
N-terminal sequence), seems to have emerged by
consensus.
The growth-inhibitory action of hirudin suggested
that the DING protein had autocrine growth-stim-
ulatory activity for ¢broblasts. As hyperprolifera-
tion of synovial ¢broblasts is believed to contribute
to the formation of the destructive pannus that is
characteristic of RA joints, the SSP/DING protein
may have the potential to promote this process [6],
even if the shorter DING protein does not have the
T-cell stimulating activity of the full SSP. Hirudin,
already used in a range of therapeutic anti-coagu-
lant applications [7^9], could also have value in
treating RA.
We now report further structural and functional
characterisation of the SSP/DING protein. We
sought to clarify the relationship, if any, between
the SSP and the hirudin-binding protein. We com-
menced with the generation and sequencing of tryptic
peptides. These amino acid sequences, and the N-
terminal sequence already obtained, were used to
specify oligonucleotide primers for detection and am-
pli¢cation of cDNA coding for the protein. Actual
and predicted amino acid sequences were used to
prepare synthetic peptide conjugates for production
of antisera, for the identi¢cation of DING, and re-
lated proteins by Western blotting. These studies
were carried out with culture medium from skin ¢-
broblasts, as used for our original study, but also
with synovial ¢broblasts, from normal and arthritic
individuals, and with synovial £uid samples. Hiru-
din-agarose chromatography, the technique origi-
nally used to detect DING in skin ¢broblast samples,
was also applied to synovial ¢broblast samples, and
to synovial £uid, and was complemented by antibody
a⁄nity chromatography.
2. Materials and methods
2.1. Synovial £uid
Human synovial £uid samples from arthritic pa-
tients were kindly provided as unlinked (unidenti¢-
able) samples by rheumatologist, Dr L. McLean, of
the Department of Molecular Medicine, University
of Auckland, Auckland, New Zealand. Individual
samples were stored at 4‡C immediately on collec-
tion into heparinised plastic centrifuge tubes, and
were centrifuged within 30 min to remove synovial
cells. Small individual samples were retained for
analysis as such, but some material from each pa-
tient was pooled into ‘RA’ or ‘non-RA’ pools; the
former contained only those samples from patients
¢rmly diagnosed as having rheumatoid arthritis,
whereas the latter contained osteoarthritis and
psoriatic arthritis samples. Where there was any
doubt over clinical diagnosis, samples were excluded
from the ‘RA’ category (L. McLean, personal com-
munication). A few small human synovial £uid sam-
ples from autopsy of non-arthritic individuals were
provided under the same conditions of anonymity
by Dr J. Vuletic, Department of Pathology, Univer-
sity of Auckland, Auckland, New Zealand. All
synovial £uid samples were routinely stored at
320‡C.
2.2. Tissue culture
Normal human diploid ¢broblasts (MRC5 or
GM1604) were maintained and subcultured as previ-
ously described [10]. Similar techniques were used to
culture human synovial ¢broblast cultures, kindly
donated by Assoc. Prof. Peter Ghosh, of the Ray-
mond Purves Bone and Joint Research Laboratories,
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University of Sydney, Sydney, Australia. These cul-
tures were established from normal (cell line 80.6)
and rheumatoid arthritis (cell lines 52.0 and 93.4)
tissues [11].
HeLa human carcinoma cells and MM96 melano-
ma cells were grown under the same conditions, as
sources of conditioned medium for hirudin-agarose
chromatography [12]. Experiments to test the e¡ects
of antisera and a⁄nity-puri¢ed antibodies on the
proliferation of ¢broblasts and synovial ¢broblasts
were carried out in 96-well culture plates, as previ-
ously described [13].
2.3. Immunochemistry
In preparing an anti-DING antiserum, we were
guided by the work of Dr Stefan Blass, from the
Department of Clinical Immunology and Rheuma-
tology, Humboldt University, Berlin, Germany,
who kindly gave us a sample of a rabbit antiserum
prepared in this way. To the 18-residue peptide,
DINGGGATLPQPLYQTSG, a C-terminal cysteine
was added, for ease of chemical conjugation. This
peptide was conjugated to keyhole limpet haemocya-
nin using maleimidocaproyl-N-hydroxysuccinimide
as linker; 3.1 mg of peptide was conjugated to 6.3
mg protein (Chiron Technologies, Clayton, Vic.,
Australia). A rabbit was immunised subcutaneously,
using standard techniques. Similar techniques were
used to make anti-peptide antisera to two putative
peptides predicted from the nucleotide sequence of a
PCR-ampli¢ed fragment of the DING cDNA. All
animal procedures were carried out by the Animal
Resources Unit of the University of Auckland, with
the approval of the institutional Animal Ethical
Committee.
Protein samples for Western blotting were sepa-
rated on 10% or 12% SDS^PAGE gels (Bio-Rad),
and electroblotted on to nitrocellulose membrane.
Primary antibodies were diluted to 1/100, and per-
oxidase-conjugated goat anti-rabbit antiserum (Sig-
ma) was used at 1/12 000 or 1/16 000 dilution as the
secondary antibody, with 3,3P-diaminobenzidine as
substrate for the staining reaction [14]. Western
blotting was carried out initially using rabbit anti-
sera, to establish the existence of reacting proteins,
and then with antibodies a⁄nity-puri¢ed from the
antisera.
2.4. A⁄nity chromatography
Hirudin-agarose a⁄nity columns were made and
used as previously described [5]. Conditioned me-
dium from cell culture (300 ml), or pooled synovial
£uid (20^50 ml) were used to load hirudin-agarose
columns. They were then washed with 75 ml of 30
mM Tris^chloride pH 7.5. Bound protein was eluted
with 100 mM sodium acetate (pH 4.1), after which
the column was washed with pH 7.5 bu¡er prior to
storage or re-use. Antibody-agarose a⁄nity columns
were made with cyanogen bromide-activated agarose
and used as previously described [15]. A⁄nity-bound
antigen was eluted with 3 M NaCl in 30 mM Tris^
HCl bu¡er (pH 7.5), or with 100 mM sodium acetate
(pH 4.1).
Antibody puri¢cation was carried out with aga-
rose-coupled peptide a⁄nity columns. These were
also made with cyanogen bromide-activated agarose,
using similar techniques (ca. 1.0 mg peptide on 2 ml
activated gel).
2.5. Amino acid sequencing and protein chemistry
For amino acid sequencing, the SDS^PAGE gel
was electroblotted onto ProBlott (Applied Biosys-
tems), the protein band was cut out of the membrane
and sequenced using a protein sequencer (Applied
Biosystems Procise 492; [16]).
Stained protein gel bands were excised for in situ
trypsin digestion as previously described [17], except
for the use of Triton X-100 (reduced, protein grade,
Calbiochem) in place of Thesit detergent. The result-
ing peptides from approximately 5 Wg of protein,
digested with 0.25 Wg trypsin, were separated by re-
verse-phase chromatography on a Phenomenex Jupi-
ter 5 Wm C18 300A column. In a 45 min gradient
elution programme, the starting eluant (0.1% tri-
£uoroacetic acid) was overlaid with a 10^70% gra-
dient of an eluant containing 80% acetonitrile and
0.0825% tri£uoroacetic acid. A total of 19 peptide
peaks were identi¢ed, eluting between 6.3 and 31.7
min, some of which were sequenced as above.
2.6. Polymerase chain reaction
Total cellular RNA was extracted from ¢broblasts
(one subcon£uent 80 cm2 £ask), using the rapid
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method of Gough [18]. Preparation of cDNA, and its
use as a template in the polymerase chain reaction
(PCR) followed our earlier practice [19]. A range of
annealing temperatures, and of magnesium ion con-
centrations, was used in an attempt to optimise re-
action conditions with the various PCR primers (Life
Technologies). Following PCR ampli¢cation of
cDNAs, each was sequenced by a modi¢ed Sanger
technique using a 377 Sequencer (ABI) in the Se-
quencing Unit of the School of Biological Sciences.
Nucleotide sequence comparisons were made by
BLAST searches in the NCBI database [20].
3. Results
The hirudin-agarose a⁄nity chromatography tech-
nique was applied to conditioned medium (300 ml)
from normal human ¢broblasts, normal synovial ¢-
broblasts, and RA synovial ¢broblasts. Electropho-
retic analysis of the concentrated hirudin-binding
protein fraction (Fig. 1A) revealed the presence of
a protein migrating close to serum albumin (ca. 60
kDa), in addition to a 40 kDa protein, as has been
previously observed with MRC5 ¢broblasts [5].
These earlier experiments demonstrated that the pro-
teins isolated were cellular products, as hirudin-aga-
rose chromatography of fresh culture medium con-
taining foetal calf serum did not yield either of these
proteins. In addition, they showed that the larger
protein had the same N-terminal sequence as human
serum albumin [5]. The 40 kDa protein corresponds
to the HSFP or DING protein, and this was con-
¢rmed by N-terminal sequencing (Table 1). The total
yield of protein was reduced in the case of a⁄nity
chromatography of RA ¢broblast-conditioned me-
dium, and the 40 kDa protein was more di⁄cult to
detect, and traces of a range of larger proteins (up to
ca. 200 kDa) were observed, though not in 15%
SDS^PAGE (but see Fig. 4). Western blotting of
these samples with the anti-DING antiserum re-
vealed a single immunoreactive species correspond-
ing to the 40 kDa protein (Fig. 1B). The albumin-like
protein was not detected by the antibodies (see also
Fig. 2). Hirudin-agarose a⁄nity chromatography
was also applied to conditioned medium from
MM96 melanoma cells, and from HeLa carcinoma
cells. In the former case, there was no signi¢cant
protein binding to the a⁄nity column. In the case
of HeLa-conditioned medium, hirudin-binding pro-
teins included the 40 kDa protein, and traces of
much larger, immunologically cross-reacting proteins
Fig. 1. Gel electrophoresis and Western blotting of hirudin-binding proteins. Proteins puri¢ed from cell culture medium by hirudin-
agarose chromatography. (A) SDS^PAGE (12%; Coomassie-stained). Tracks, from left, are protein standards (lane a), MRC5 ¢bro-
blasts (lanes b and c), rheumatoid arthritis synovial ¢broblasts (lane d) and normal synovial ¢broblasts (lane e). (B,C) Western blots
of 10% SDS^PAGE, developed with DING antiserum. Tracks are normal synovial ¢broblasts (lane f), rheumatoid ¢broblasts (lane g),
MRC5 ¢broblasts (lane h) and HeLa carcinoma cells (lanes i and j). The positions of protein standards are noted on the left, and the
calculated molecular weights of protein bands are on the right, in kDa in each case.
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of molecular weights about 150 and 200 kDa (Fig.
1C).
When pooled RA synovial £uid was subjected to
hirudin-agarose a⁄nity chromatography, the eluate
contained the 60 kDa albumin-like protein, and a
high-molecular weight band, but there was no 40
kDa component (Fig. 2A). Similar results were ob-
tained with pooled non-RA synovial £uid (not
shown). The anti-DING N-terminal antiserum was
used to con¢rm the identity of DING-related pro-
teins in synovial £uid. Fig. 2B shows a Western
blot of pooled synovial £uid samples that had been
subjected to hirudin-agarose chromatography, to-
gether with samples of the 40 kDa protein from ¢-
broblasts. Both RA and non-RA pooled samples
contain high-molecular weight material (ca. 200
Table 1
Amino acid sequences of DING protein and derived tryptic peptides
HPLC peak Elution time (min) Yield (pmol) Sequence
4a 12.4 7.9 HFSAEL-
b (doublet) 9.6 LTGTSL-
7 13.3 8.9 ITTWNQLPATGR
8 17.0 12.8 LAFLNNDYSQFGTGTK
13 23.5 8.0 DINGGGATLPQPLYQTSGVLTAGFAPYTGV-
40 kDa protein ^ ^ DINGGGATLPQPLYQTSGVLTA-
The listed peptides were separated by reverse-phase HPLC from a tryptic digest of a DING protein sample from SDS^PAGE. The
time of elution in the gradient elution programme (details in Section 2) is listed, as is the yield of the ¢rst PTH amino acid. The ¢nal
entry is an N-terminal sequence obtained from an electroblotted sample of the DING protein from SDS^PAGE.
Fig. 2. Hirudin-binding proteins from human synovial £uid. Proteins puri¢ed from human synovial £uid by hirudin-agarose chroma-
tography. (A) Pooled rheumatoid arthritis synovial £uid passed through column, and eluted with 1 M NaCl (track b), and 1 M NaCl
pH 4.1 (track a), to yield two protein fractions, analysed by SDS^PAGE (10% gel, Coomassie-stained). (B) Western blot analysis
(10% SDS^PAGE; DING antiserum) of RA synovial £uid fractions puri¢ed by hirudin-agarose chromatography. Tracks f and g: as
for A, a and b. Tracks c and d: pooled non-RA synovial £uid fractionated in the same way. Track e: individual synovial £uid sam-
ple. Track h: hirudin-binding protein from rheumatoid arthritis synovial ¢broblast culture medium. Track i: hirudin-binding protein
from MRC5 ¢broblast culture medium. In each case, the positions of protein standards are noted on the left, and the calculated mo-
lecular weights of protein bands are on the right, in kDa in each case.
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kDa), which cross-reacts with the anti-DING antise-
rum, but there is no evidence for a 40 kDa version of
the DING protein in any of these samples. These
experiments indicate that the high-molecular weight
form of the DING protein in synovial £uid can bind
to hirudin-agarose. An individual RA synovial £uid
(lane e, Fig. 2B), showed a doublet pattern of high-
molecular weight bands (at ca. 200 kDa and 180
kDa) in the Western blot.
Further characterisation of the DING protein
started with an in situ tryptic digest of the 40 kDa
protein puri¢ed from MRC5 ¢broblast-conditioned
medium. Although 19 peaks were detected, only
about half were in su⁄cient yield to attempt sequenc-
ing, and several of these gave multiple sequences,
which could not be distinguished. Table 1 lists the
amino acid sequences obtained from the remaining
peptides, together with a new N-terminal sequence
for the intact 40 kDa protein. The ‘yield’ values
quoted in this table represent the PTH amino acid
yield in the ¢rst sequencing cycle; these ranged from
8 to 13 pmol, suggesting that they originated from
the same protein in the digest. Peak 4 yielded a dou-
blet, the partial sequences of which were distinguish-
able from the di¡erent intensities of the PTH amino
acids. Peak 13 gave a partial sequence which was
identical with the N-terminus of the whole protein,
and which extended this sequence by about eight
residues. Peaks 7 and 8 corresponded to discrete
Fig. 3. The partial nucleotide sequence of the putative cDNA fragment of the DING protein, and the derived amino acid sequence.
The numbering refers to the amino acid sequence. The amino acid sequences used to specify peptides for conjugation and immunisa-
tion are in bold. The amino acid sequence showing homology with the DEP domain of the dishevelled gene is underlined. The nucleo-
tide sequence used as a reverse PCR primer (primer 3), in conjunction with DING-derived forward primers, is bold and underlined.
Fig. 4. Western blotting of hirudin-binding proteins with DING
and DSH antisera. In A, a 10% SDS^PAGE separation of pro-
teins bound to hirudin-agarose from RA synovial ¢broblast me-
dium (lane a) and from HeLa cell medium (lane d), and two
synovial £uid samples (lanes b and c) was blotted and probed
with the DING antiserum. In B, an identical protein separation
was probed with the DSH antiserum, so that lane e contains
RA ¢broblast proteins, lanes f and g are synovial £uid samples,
and lane h contains HeLa proteins. A molecular weight scale,
in kDa, is to the right.
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tryptic peptides, which were completely sequenced.
These peptide sequences were used to specify degen-
erate oligonucleotide primers, which were used in
PCR reactions with ¢rst-strand cDNA, made from
total ¢broblast RNA, as a template. A human neu-
trophil cDNA library was also used as a template.
Several di¡erent forward primers, both degenerate
and non-degenerate, were derived from the N-termi-
nal sequence of the DING protein. In conjunction
with reverse primers based on all of the other
DING peptide sequences, or with 3P-RACE primers,
no coherent PCR fragments were obtained, despite
the use of a wide range of conditions for the PCR,
and a variety of templates (not shown). Forward and
reverse primers both based on DING internal peptide
sequences were more successful in the PCR. Using
the forward primer 1 (5P-CTGACCGGCACCTC-
CCTG-3P), based on peptide 4b, and the degenerate
reverse primer 2, based on peptide 7 (5P-DG-
TRGCDGGCAGCTGGTTCCADGTDGTGAT-3P),
an approximately 840-nucleotide fragment was ampli-
¢ed from cDNA from MRC5 ¢broblasts, from nor-
mal synovial ¢broblasts, and from RA synovial ¢bro-
blasts (not shown). The annealing temperature for
this PCR reaction was 47‡C, and the Mg2 concen-
tration was 1.5 mM. We were unable to clone this
cDNA, and sequenced it directly from the PCR prod-
uct. The partial nucleotide sequence of the fragment
from MRC5 ¢broblasts, comprising all of the reliable
sequence determined directly from the PCR product
(about 730 nucleotides), is shown in Fig. 3, together
with the derived amino acid sequence.
The 5P portion of this fragment shows a high de-
gree of sequence homology with the DEP domain of
the dishevelled gene (dsh), ¢rst identi¢ed as having a
role in developmental polarity in Drosophila mela-
nogaster. Over a 353-nucleotide sequence, complete
identity with a human dishevelled 3 (DVL3) mRNA
[21] sequence was obtained in a BLAST search.
Much of the sequence is identical with sequences
within a 350 kb fragment of human chromosome 3
(GenBank accession number: NT022424.2/
HS322580). The sequences 10^63, 64^195 and 196^
600 in Fig. 3 correspond to sequences 110510^
110563, 111168^111299 and 111484^111888, respec-
tively, within this chromosomal fragment. Also
marked in Fig. 3 is the sequence used to specify a
non-degenerate reverse PCR primer, primer 3, (5P-
TCCATCACCAGTTCCATCC-3P). Used in con-
Fig. 5. Western blotting of synovial £uid samples with DING, DSH and SPN antisera. A, B and C each show the Western blotting
of three identical arrays of arthritis synovial £uid samples separated on 10% SDS^PAGE with the DING (A), DSH (B) and SPN (C)
antibodies. The lanes are labelled r, o, p or u to indicate samples of rheumatoid, osteo-, psoriatic or undetermined arthritis synovial
£uid. D is a single sample of synovial £uid from an apparently non-arthritic individual. Positions of molecular weight standards, in
kDa, are marked at the right.
Fig. 6. Western blotting of antibody a⁄nity-puri¢ed DING/SSP
protein. Pooled synovial £uid was run through an SPN anti-
body-agarose a⁄nity column. The eluted protein fraction was
run on 10% SDS^PAGE, and subjected to Western blotting
with DING antibodies (lane a), DSH antibodies (lane b), and
with the secondary antibody only (lane c). The molecular
weight in kDa, calculated from the gel calibration is marked on
the right.
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junction with DING-derived forward primers, we
were still unable to obtain PCR products linking
the DING N-terminus to the putative internal frag-
ment (not shown).
Two peptides were synthesised, corresponding to
potentially immunogenic sites within the putative
DEP domain, and the distal, C-terminal part of the
fragment ([22]; see Fig. 3). A C-terminal cysteine was
added to each, for conjugation. HNVEGFTDR-
REARKC was coupled to keyhole limpet haemocya-
nin and GGQQSQGPNSRPEC was coupled to
diphtheria toxoid, and each was used for rabbit anti-
serum production, as described in Section 2.
The antiserum against the DEP domain peptide
was named the DSH antiserum, and the antiserum
against the distal peptide was referred to as the SPN
antiserum (‘dish’ and ‘spoon’). That the DING and
DSH antisera detect the same proteins in hirudin-
agarose-puri¢ed cell culture media is shown in Fig.
4. Traces of a 200 kDa cross-reacting protein were
present in both RA synovial ¢broblast- and HeLa-
derived samples. A 40 kDa protein was also detected
by both antisera, as were cross-reacting proteins of
intermediate size, about 140^180 kDa. Synovial £uid
samples were also tested at the same time, and it is
clear that the DSH antibodies also detect a 200 kDa
protein in these samples.
More extensive comparison of human synovial £u-
id samples with the DING, DSH and SPN antibod-
ies is shown in Fig. 5. It seems most probable, from
these results, that the DING, DSH and SPN anti-
bodies are each recognising the same synovial £uid
protein. To con¢rm this deduction, antibody-agarose
columns prepared with the DING and SPN antibod-
ies were used to isolate proteins by a⁄nity chroma-
tography from pooled synovial £uid. Electrophoresis
and Western blotting of the pooled, concentrated
eluates indicated that a 200 kDa protein binding to
the SPN antibody column was detectable with DING
and DSH antibodies (Fig. 6), and that a similar
DING antibody-binding protein cross-reacted with
SPN and DSH antibodies (not shown). The DING
and SPN antisera were prepared with di¡erent car-
rier proteins, so that the cross-reactivity is not due to
antibodies against any residual carrier protein epi-
topes.
In preliminary experiments, the DING, DSH and
SPN antisera were tested for their ability to inhibit
¢broblast growth. It was clear from these experi-
ments that antibodies to the N-terminal DING pep-
tide had no e¡ect upon the growth rate of normal or
RA ¢broblasts, but the other two antisera gave in-
hibitory results (not shown). Both the DING and the
DSH antisera were raised with peptide-haemocyanin
conjugates, so we can be sure that anti-haemocyanin
antibodies were not responsible for the DSH antise-
rum result. On this basis, a⁄nity-puri¢ed DSH and
SPN antibodies were re-tested, and Table 2 shows
the e¡ects of these antibody preparations on the pro-
liferation of ¢broblasts. Results with the DSH anti-
bodies are ambiguous, with no evidence for an e¡ect
on RA ¢broblasts, but the SPN antibodies are e¡ec-
Table 2
E¡ect of DSH and SPN antibodies on ¢broblast proliferation
Antibody Concentration (Wg/ml) Normal ¢broblasts RA ¢broblasts
A540nm (% control) A540nm (% control)
Control (no antibody) ^ 0.340 þ 0.01 100 0.290 þ 0.02 100
DSH 11 0.193 þ 0.02 57 0.272 þ 0.02 94
33 0.286 þ 0.04 84 0.291 þ 0.03 100
100 0.278 þ 0.02 82 0.298 þ 0.02 103
SPN 16 0.052 þ 0.02 15 0.157 þ 0.04 54
47 0.048 þ 0.01 14 0.110 þ 0.02 38
140 0.054 þ 0.03 16 0.081 þ 0.03 28
Normal ¢broblasts (GM1604) or RA ¢broblasts (strain 93.4) were inoculated sparsely into triplicate microwells on a culture plate.
After 24 h, the medium was changed for medium containing antibodies, and similarly changed after a further 48 h. After a further
72 h, all wells were ¢xed, Giemsa-stained, and measured with an ELISA photometer at 540 nm. The absorbance of con£uent, control
wells (6000 cells/well) was set at 100%, and test well readings expressed as a percentage of this [13]. Each value is the mean of a tripli-
cate determination.
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tive growth inhibitors, for both normal and RA ¢-
broblasts.
4. Discussion
The 40 kDa hirudin-binding protein, or DING
protein, previously identi¢ed as being secreted by
human skin ¢broblasts, is also produced and secreted
by human synovial ¢broblasts, from both normal
and rheumatoid arthritis tissue. In RA ¢broblasts,
this 40 kDa protein is present in smaller amounts,
but a secreted high-molecular weight DING cross-
reactive protein was detected in some experiments.
On the basis of this immunochemical cross-reactivity,
and the molecular weight of approximately 200 kDa,
this protein appears to be identical with the SSP, also
known as p205, which is known to contain a 40 kDa
DING polypeptide sequence [4]. A cross-reactive
protein of intermediate molecular weight was also
sometimes detected. Traces of all three types of
DING cross-reactive proteins in HeLa-conditioned
medium support the concept of a precursor^product
relationship between the SSP and the DING protein,
but this remains to be con¢rmed. Experiments with
synovial £uid showed that the SSP is able to bind to
hirudin-agarose, con¢rming that it would be detect-
able if present in conditioned medium, since even
trace quantities would be concentrated by the a⁄nity
chromatography. It is signi¢cant that all three ¢bro-
blast types express the SSP/DING gene, as indicated
by the similar outcomes of PCR experiments with
cDNA from each cell type as template, and primers
1 and 2. It appears that RA ¢broblasts may have a
limited capacity to convert the SSP into the DING
protein, but we cannot rule out the possibility that
di¡erent DING and SSP genes are transcribed, or
that a common transcript is subjected to di¡erential
post-transcriptional processing.
Synovial £uid samples contain a protein of ap-
proximately 200 kDa that cross-reacts with antibod-
ies to the DING protein, and is thus assumed to be
the SSP. The SSP is present in both RA and non-RA
synovial £uid, indicating that it is not speci¢cally
associated with rheumatoid arthritis, and, in fact, is
present in normal synovial £uid. This conclusion is
not an artefact of the pooling of synovial £uid sam-
ples, as the DING antibodies detected a similar pro-
tein band in almost all of the individual synovial
£uid samples, including samples from non-arthritic
individuals. This outcome indicates that di⁄culties
in the diagnosis of RA may be largely irrelevant to
this project. Even after hirudin-agarose chromatog-
raphy, which would be expected to concentrate traces
of DING protein from synovial £uid, a 40 kDa
DING protein band was not detected. There was
thus no evidence for the conversion of the SSP into
the DING protein in synovial £uid. It is possible that
this conversion may occur, but that DING is e¡ec-
tively removed by synovial cells.
We cannot explain why it has been so di⁄cult to
initiate PCR ampli¢cation from the DING N-termi-
nal coding region. Other research groups have expe-
rienced similar di⁄culties (B. Stuhlmuller; R. Mans-
¢eld, personal communications), and the sequence
has not yet been reported from the Human Genome
Project. The genetic evidence for the identi¢cation of
our PCR fragment as part of the DING protein is
very slender, as sequencing directly from a PCR
product has excluded any regions of primer identity,
and none of the known tryptic peptide sequences
were detected within it. However, the immunochem-
ical evidence supports this conclusion. Antibodies to
peptide sequences predicted from the PCR fragment
bind to the same protein as antibodies to the DING
N-terminal peptide sequence.
The observed homology with DEP domains o¡ers
few clues as yet to the function of the DING protein.
Dishevelled is a ubiquitous gene family involved in
development and growth regulation. The DEP do-
main of the dishevelled protein is found in a variety
of proteins, including pleckstrin, a substrate for pro-
tein kinase C in haematopoetic cells. In addition to
interaction with protein kinases, another common
function of DEP domains may involve a role in
GTP^GDP exchange reactions [23]. It should also
be noted that we have previously identi¢ed the
DING protein in ¢broblast lysates, so it is also a
cytoplasmic protein [5]. The DEP domain may be
important to a cytoplasmic function, but has no sig-
ni¢cance when SSP/DING is extracellular.
Our original observation in this ¢eld was that hi-
rudin partially inhibited normal ¢broblast growth,
and that we detected the DING protein, rather
than thrombin, as a hirudin-binding component [5].
On this basis, it could be predicted that antibodies to
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the DING protein might also be growth inhibitory
for ¢broblasts. This prediction was not con¢rmed
when antibodies to the DING epitope were tested,
but anti-DSH antibodies had equivocal growth-in-
hibitory activity, whilst anti-SPN antibodies were ef-
fective growth inhibitors, against both synovial and
non-synovial ¢broblasts. These results con¢rm a
synovial stimulatory role for the SSP/DING protein,
and indicate that the SPN domain may be responsi-
ble for this function. As each antiserum recognises a
single SSP/DING epitope, the degree of antibody
cross-linking will be small. Poor immunoprecipita-
tion is con¢rmed in immunodi¡usion experiments
with antibodies and synovial £uid or DING concen-
trates (results not shown). SPN antibodies may be
e¡ective growth inhibitors by binding directly to
the SPN domain. DSH antibodies, which bind to a
nearby site, may thus have a partial inhibitory e¡ect,
whereas DING antibodies, binding to a more remote
site, are ine¡ective. It is notable that the lowest con-
centration of the DSH antibody nevertheless gave
the greatest degree of growth inhibition. This may
represent an immunoprecipitation e¡ect, for which
both antibody and antigen concentrations are opti-
mal. Neither of the SSP/DING protein domains that
we have identi¢ed, nor any of the other amino acid
sequences, has any resemblance to known protein-
ases, so it seems possible that the proteolytic activity
reported earlier [5] may have been due to trace con-
taminants in the proteins eluted from hirudin-aga-
rose columns.
It has recently been reported that normal synovial
¢broblasts may be displaced in RA synovia, by in-
¢ltration of less di¡erentiated ¢broblast-like synovio-
cytes with di¡erent phenotypic characteristics [24].
This alteration in cell type could be connected with
the di¡erent processing of the SSP/DING protein by
RA ¢broblasts that we have observed. It is clear
from our observations that both RA and non-RA
¢broblasts express an SSP/DING gene, and respond
to SSP/DING as an autocrine growth stimulator,
though the antibody inhibition experiments suggest
a di¡erential sensitivity to this stimulation.
The expression of SSP/DING in a human tumour
cell suggests that, as a growth-modulatory factor, it
may have wider signi¢cance than in the synovial sys-
tem. The DING N-terminal amino acid sequence has
been detected in a 38 kDa genistein-binding protein
(H. Kim and S. Barnes, personal communication).
This may help explain the growth-inhibitory activity
of genistein against human breast carcinomas; this
phenomenon is apparently independent of the inhi-
bition of tyrosine kinases by genistein [25].
In summary, we have characterised an internal
fragment of the human 40 kDa DING protein, and
shown that it is present within a much larger 200
kDa protein, secreted by some cell types and found
in synovial £uid. This protein is identical with, or is
closely related to, the 205 kDa SSP, which has been
previously reported [4]. The production and occur-
rence of this protein is not unique to RA cells or
synovial £uid. Although the larger protein may be
proteolytically processed to the smaller, the 40 kDa
DING protein has not been found in synovial £uid.
Antibodies to a DING protein domain inhibit pro-
liferation of DING-secreting cells, con¢rming an ear-
lier ¢nding that DING had an autocrine stimulatory
e¡ect on such cells [5].
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